Cited by 323Chronic Obstructive Pulmonary Disease (COPD) ResearchOral microbiology and periodontitis researchAsthma and respiratory diseases

Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease

Open access
Huang, Yvonne J., Sethi, Sanjay, Murphy, Timothy, Nariya, Snehal, Boushey, Homer A., Lynch, Susan V.·2014·Journal of Clinical Microbiology

Abstract

Specific bacterial species are implicated in the pathogenesis of exacerbations of chronic obstructive pulmonary disease (COPD). However, recent studies of clinically stable COPD patients have demonstrated a greater diversity of airway microbiota, whose role in acute exacerbations is unclear. In this study, temporal changes in the airway microbiome before, at the onset of, and after an acute exacerbation were examined in 60 sputum samples collected from subjects enrolled in a longitudinal study of bacterial infection in COPD. Microbiome composition and predicted functions were examined using 16S rRNA-based culture-independent profiling methods. Shifts in the abundance (≥ 2-fold, P < 0.05) of many taxa at exacerbation and after treatment were observed. Microbiota members that were increased at exacerbation were primarily of the Proteobacteria phylum, including nontypical COPD pathogens. Changes in the bacterial composition after treatment for an exacerbation differed significantly among the therapy regimens clinically prescribed (antibiotics only, oral corticosteroids only, or both). Treatment with antibiotics alone primarily decreased the abundance of Proteobacteria, with the prolonged suppression of some microbiota members being observed. In contrast, treatment with corticosteroids alone led to enrichment for Proteobacteria and members of other phyla. Predicted metagenomes of particular microbiota members involved in these compositional shifts indicated exacerbation-associated loss of functions involved in the synthesis of antimicrobial and anti-inflammatory products, alongside enrichment in functions related to pathogen-elicited inflammation. These trends reversed upon clinical recovery. Further larger studies will be necessary to determine whether specific compositional or functional changes detected in the airway microbiome could be useful indicators of exacerbation development or outcome.

Integrity signals

Registry

Crossref · 10.1128/jcm.00035-14

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Culture-independent studies comparing bacterial communities at baseline and during exacerbations in the airways of patients with COPD, cystic fibrosis, or bronchiectasis consistently report no increase in bacterial burden and no decrease in community diversity during exacerbations.

    “With remarkable consistency, all studies report no increase in bacterial burden and no decrease in community diversity during exacerbations.”

    From The microbiome and critical illness (2016) · cites this paper as [132]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Huang, Y. J., Sethi, S., Murphy, T., Nariya, S., Boushey, H. A., & Lynch, S. V.
Affiliations
  • University of California, San Francisco (US)
  • Buffalo VA Medical Center (US)
  • University at Buffalo, State University of New York (US)
Venue
Journal of Clinical Microbiology
Published
2014-08
Volume
52
Issue
8
Pages
2813-2823
ISSN
  • 0095-1137 (ISSN-L)
  • 1098-660X
OpenAlex
W2135623379
Cited by
323
References
48
Citations by year
2026: 11 · 2025: 12 · 2024: 25 · 2023: 25 · 2022: 30 · 2021: 33 · 2020: 35 · 2019: 28 · 2018: 24 · 2017: 38 · 2016: 27 · 2015: 29 · 2014: 6
FWCI
26.69
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Microbiology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
National Heart, Lung, and Blood Institute (K23HL105572, HL105572)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
  • Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
Keywords
chronic obstructive pulmonary disease, COPD exacerbations, airway microbiome, sputum microbiota, Proteobacteria, antibiotic therapy, oral corticosteroids, inflammation
MeSH terms
Aged, Aged, 80 and over, DNA, Bacterial, DNA, Ribosomal, Humans, Longitudinal Studies, Male, Middle Aged, Phylogeny, Respiratory System, RNA, Ribosomal, 16S, Sputum, Cluster Analysis, Sequence Analysis, DNA, Proteobacteria, Pulmonary Disease, Chronic Obstructive, Microbiota

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review